68295-80-7

Basic information

• Product Name: (1S,5S)-5-Hydroxy-cyclohex-3-enecarboxylic acid methyl ester
• Synonyms: (1S,5S)-5-Hydroxy-cyclohex-3-enecarboxylic acid methyl ester
• CAS NO: 68295-80-7
• Molecular Weight: 156.181
• Mol File: 68295-80-7.mol
• Article Data: 22

Chemical Properties

• CAS DataBase Reference: (1S,5S)-5-Hydroxy-cyclohex-3-enecarboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,5S)-5-Hydroxy-cyclohex-3-enecarboxylic acid methyl ester(68295-80-7)
• EPA Substance Registry System: (1S,5S)-5-Hydroxy-cyclohex-3-enecarboxylic acid methyl ester(68295-80-7)

Safety Data

• Hazardous Substances Data: 68295-80-7(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 109667-78-9 N-(4-chloro-7-oxo-6-oxabicyclo[3.2.1]octan-3-yl)acetamide 
• 4720-83-6 6-oxabicyclo[3.2.1]oct-3-en-7-one 
• 124-41-4 sodium methylate 
• 76140-13-1 endo-4-iodo-6-oxabicyclo<3,2,1>octan-7-one 
• 4771-80-6 1,2,5,6-tetrahydrobenzoic acid 
• 108-05-4 vinyl acetate 
• 54911-89-6 cis-methyl 5-hydroxycyclohex-3-enecarboxylate 
• 72359-56-9 3-acetoxy-5-carbomethoxy-1-cyclohexene 
• 4720-83-6 6-oxabicyclo<3.2.1>-oct-3-en-7-one 
• 79433-96-8 methyl 5-hydroxy-3-cyclohexenecarboxylate 
• 935-79-5 cis-1,2,3,6-tetrahydrophthalic anhydride 
• 19914-76-2 (1S-cis)-6-Chlorcarbonyl-3-cyclohexen-1-carbonsaeure-methylester 
• 119719-61-8 (1R,4R,5R)-4-iodo-6-oxabicyclo[3.2.1]octane-7-one 

Downstream Products

• 126640-65-1 3R-Hydroxycyclohex-4-en-1S-carboxylate 
• 92-52-4 biphenyl 
• 344336-46-5 2-((1S,5S)-5-Methoxycarbonyl-cyclohex-2-enyl)-malonic acid dimethyl ester 
• 108-95-2 phenol 
• 122762-07-6 (1R,5S)-5-(2-Ethynyl-tetrahydro-pyran-2-yloxy)-cyclohex-3-enecarboxylic acid methyl ester 
• 122762-07-6 (1S,5S)-5-(2-Ethynyl-tetrahydro-pyran-2-yloxy)-cyclohex-3-enecarboxylic acid methyl ester 
• 87830-10-2 trans-5-(methoxycarbonyl)-2-cyclohexenyl chloride 
• 54911-89-6 methyl trans-5-hydroxycyclohex-3-enecarboxylate 
• 54911-89-6 (1R,5R)-methyl-5-hydroxycyclohex-3-enecarboxylate 
• 115181-98-1 cis-3-Acetoxy-5-carbomethoxycyclohexene 
• 677745-93-6 cis-3-Acetoxy-5-carbomethoxycyclohexen 
• 123453-95-2 (1S,5S)-(-)-5-(hydroxymethyl)-2-cyclohexen-1-ol 
• 127308-75-2 (1R,5R)-5-(hydroxymethyl)-2-cyclohexen-1-ol 
• 70144-91-1 methyl (1R,3S)-3-hydroxycyclohexane-1-carboxylate 

Relevant articles and documents

Dynamic kinetic resolution with enzyme and palladium combinations

The dynamic kinetic resolution of certain allyl acetates has been achieved by enzymatic hydrolysis to the corresponding allyl alcohols. In the presence of a palladium catalyst, the allyl acetate is racemised, allowing a dynamic resolution to take place.

Asymmetric palladium-catalyzed allylic alkylation using dialkylzinc reagents: A remarkable ligand effect

A serendipitously discovered palladium-catalyzed asymmetric allylic alkylation reaction with diorganozinc reagents, which displays broad functional group compatibility, is reported. This novel transformation hinges on a remarkable ligand effect which overrides the standard "umpolung" reactivity of allyl-palladium intermediates in the presence of dialkylzincs. Owing to its mild conditions, enantioselective allylic alkylations of racemic allylic electrophiles are possible in the presence of sensitive functional groups. Umpole-me-not: A serendipitously discovered palladium-catalyzed asymmetric allylic alkylation reaction with diorganozinc reagents displays broad functional group compatibility. This novel transformation hinges on a remarkable ligand effect which overrides the standard "umpolung" reactivity of allyl-palladium intermediates in the presence of dialkylzinc compounds.

E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation. These E-selection antagonists have the general formula (Ia) below.